Independent publication. We may earn a commission when you use certain links. Learn more.
WWeight Care Compass Explore ↓
Wave 1

HealthRx Alternatives: Online GLP-1 Providers Compared

Compare HealthRx alternatives including Mochi Health, Henry Meds, Ro and Hims by payment model, medication access and program structure.

Reviewed August 19, 2026 · Independent editorial content

HealthRx is one of several telehealth options for prescription weight-management care. The right alternative depends less on brand recognition than on whether you want bundled cash-pay pricing, insurance navigation, FDA-approved medications, compounded medication access, or a particular type of ongoing support.

Mochi Health

Mochi currently advertises compounded semaglutide and tirzepatide with price varying by dose, alongside branded medication options. Its model is worth comparing if you want a program that can span compounded and brand-name pathways.

Henry Meds

Henry Meds markets cash-pay weight-management programs and says pricing can include provider visits, medication, supplies and ongoing support. It offers multiple medication formats, so compare the exact program rather than assuming every Henry plan is equivalent to HealthRx.

Ro

Ro's Body program uses a membership fee that is separate from the medication cost. Its positioning is particularly relevant for people seeking FDA-approved GLP-1 access and help navigating insurance coverage.

Hims

Hims operates a weight-loss membership and offers medication options that can include FDA-approved GLP-1s. Pricing and availability vary, so verify the current treatment page rather than relying on older compounded-GLP-1 advertising.

Where HealthRx differs

HealthRx's clearest differentiator is a bundled cash-pay price for compounded semaglutide or tirzepatide. For a cash-pay shopper who wants fewer separate line items, that can simplify comparison. For someone focused on an FDA-approved brand or insurance coverage, a different platform may fit better.

Sources & verification

We use primary sources for time-sensitive commercial and regulatory claims.

Last reviewed: August 19, 2026